Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial성인에서 홍역 벡터 기반 SARS-CoV-2 백신 후보 V591의 안전성 및 면역원성: 1/2상 무작위, 이중 맹검, 위약 대조, 용량 범위 시험 결과Clinical Trial Published on 2022-01-012022-09-11 Journal: EBioMedicine [Category] SARS, 임상, 치료기술, [키워드] Adverse adverse events anti-SARS-CoV-2 assigned convalescent serum COVID-19 COVID-19 disease Culture Day death dose double-blind event fatigue headache healthy humoral immunogenicity immunogenicity Inc. infectious dose injection Injection-site pain Intramuscular injection median multicentre myalgia neutralising antibody occurred Older participant Placebo placebo-controlled randomised response Safety SARS-CoV-2 SARS-CoV-2 vaccine screened secondary secondary outcome Serious Adverse Event Serious Adverse Events serum Sharp single dose subsidiary TCID tissue tissue culture titre titres Trial USA Vaccine [DOI] 10.1016/j.ebiom.2021.103811 PMC 바로가기 [Article Type] Clinical Trial
Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months follow-up신장 이식 및 만성 투석 환자에 대한 tozinameran(BNT162b2) mRNA 백신의 영향: 3-5개월 추적Article Published on 2022-01-012022-09-11 Journal: Journal of Nephrology [Category] SARS, 치료기술, [키워드] antibody Antibody Response BNT162b2 calcineurin Cancer changes in cohort study Control controls COVID-19 COVID-19 mRNA Vaccination Determining diabetes dialysis drug level End-stage renal disease events Factor ferritin Follow-up healthcare Hemodialysis humoral humoral immunogenicity hypertension identify IgG antibody Impact Infection infection rate infections kidney transplant kidney transplant recipients Kidney transplantation log lymphocyte Lymphocyte count measure modality morbidity mounted mRNA vaccination mRNA vaccine mTOR mTOR inhibitor Older age Patient patients Peritoneal dialysis PROTECT recipient reduced renal renal disease renal replacement therapy replacement therapy required risk Risk assessment S1/S2 Serum ferritin Subsequent infection vaccination Vaccine Vaccines viral infections women [DOI] 10.1007/s40620-021-01210-y PMC 바로가기 [Article Type] Article
Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies전임상 연구에서 코로나19 불활화 백신(CoviVac)의 장기 체액성 면역원성, 안전성 및 보호 효능Article Published on 2021-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] SARS, 신약개발, 진단, [키워드] allergenic animal model animal models anti-SARS-CoV-2 IgG clinical trial clinical trials country Course COVID-19 COVID-19 pandemic decrease demonstrated Effects Efficacy hamster hamsters humoral immune response humoral immunogenicity immune response immunization immunogenicity implementation inactivated Inactivated vaccine intranasal Live virus mice multitude NAb NAbs Neutralizing Neutralizing antibodies non-human primates preclinical study Protective reproductive robust robustness rodent rodents Safety SARS-CoV-2 severe pneumonia significantly stability teratogenic teratogenic effects the vaccine the vaccines These data Toxicity Vaccine vaccine platform virion [DOI] 10.1080/22221751.2021.1971569 PMC 바로가기 [Article Type] Article
Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran이란의 보건 복지사에서 스푸트니크 대 코비드 -19 백신의 투여 후 부작용 및 면역 원성Article Published on 2021-11-022022-09-01 Journal: Scientific Reports [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] administration adverse effect adverse effects adverse event adverse events age antibody body pain chilling COVID COVID-19 COVID-19 vaccine detectable Diseases drowsiness Effect Epidemiology evaluated Evidence fatigue female Fever first and second dose first dose headache Health care Health care worker healthcare healthcare worker Healthcare workers humoral immunogenicity immunogenicity independent individuals injection injection site interim results Iran joint joint pain male Medical research men Microbiology neutralizing antibody observational study Pain Participants provided Randomized controlled trials receiving released reported SARS-CoV-2 neutralizing antibody SARS-CoV-2 RBD second dose second dose of vaccine side Side effect Side effects significantly more Support the mean the vaccine Vaccine women [DOI] 10.1038/s41598-021-00963-7 PMC 바로가기 [Article Type] Article
Measuring cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine (BNT126b2) in patients on maintenance haemodialysis유지 혈액투석 환자에서 SARS-CoV-2 mRNA 백신(BNT126b2)의 세포 및 체액 면역원성 측정Article Published on 2021-09-012022-09-12 Journal: EBioMedicine [Category] MERS, SARS, 진단, [키워드] cellular Haemodialysis humoral immunogenicity mRNA vaccine Patient SARS-CoV-2 [DOI] 10.1016/j.ebiom.2021.103567 PMC 바로가기 [Article Type] Article
Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis혈액투석 환자에서 SARS-CoV-2 mRNA 백신의 세포 및 체액 면역원성Article Published on 2021-08-012022-09-11 Journal: EBioMedicine [Category] MERS, SARS, 변종, 진단, [키워드] ACE2-RBD addressed Alpha anti-SARS-CoV-2 IgG Beta binding BNT162b2 cellular Cellular immune response cellular immune responses Cluster COVID-19 cytokine detectable dialysis diminished Efficacy elicited Epsilon Follow-up Haemodialysis Horizon humoral Humoral and cellular immune responses humoral immune response humoral immune responses humoral immunogenicity immune responses Immunity Immunocompromised immunogenicity Immunoglobulin immunoglobulins increased risk individual initiative interferon interferon γ Longevity Mortality mRNA vaccination mRNA vaccine multiplex networking neutralization of BNT162b2 Patient peptides plasma protective immunity renal renal insufficiency Research response Saliva SARS-CoV-2 SARS-CoV-2 spike peptide SARS-CoV-2 vaccine SARS-CoV-2 variant serum significantly state Stimulation T-cell Tourism two-dose regimen vaccination Vaccine vaccine responses variants variants of concern Virus neutralization was reduced [DOI] 10.1016/j.ebiom.2021.103524 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial후보 중동 호흡기 증후군 코로나바이러스 바이러스 매개 백신의 안전성 및 면역원성: 용량 증량, 공개, 비무작위, 비통제, 1상 시험Article Published on 2020-07-012022-08-13 Journal: The Lancet. Infectious Diseases [Category] 임상, [키워드] absence adverse event AID All participant All participants antibody Antigen Arabian Peninsula assigned baseline cellular cellular and humoral immunogenicity cellular response ChAdOx1 ChAdOx1 MERS clinical clinical development clinical trial coronavirus Department described dose dose-escalation doses effective elicit ELISA enzyme enzyme-linked immunospot expressing finding FIVE Follow-up follow-up period full-length full-length spike surface glycoprotein funding healthy hepatitis B hepatitis B surface antigen hepatitis C hepatitis C antibodies hepatitis C antibody High-dose high-dose group HIV antibodies humans humoral humoral immunogenicity IgG immunogenicity ImmunoSpot Infection interferon interferon-γ-linked enzyme-linked immunospot intermediate-dose group Intervention Intramuscular injection low-dose Medicine MERS MERS-CoV MERS-CoV spike antigen Middle East Middle East respiratory syndrome Coronavirus Mild mild in severity moderate neutralisation neutralisation assay Neutralising Antibodies nine Occurrence Open-label Oxford participant Phase 1 phase 1 trial pre-vaccination test pre-vaccination tests pregnancy test progression proportion Pseudotyped virus public health Registered Relative risk reported resolved respiratory respiratory syndrome coronavirus response risk Safe Safety Saudi Arabia Serious Adverse Event Serious Adverse Events severe adverse event significant increase significantly higher simian adenovirus-vectored vaccine single dose Support surface antigen Surface glycoprotein T-cell tested Tolerability trials tropical medicine urinary pregnancy test vaccination vectored vaccine Viral viral particle Viral particles virus neutralising assay virus neutralising assays was done women [DOI] 10.1016/S1473-3099(20)30160-2 PMC 바로가기 [Article Type] Article
Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in miceResearch Article Published on 2019-10-072022-10-28 Journal: PLoS ONE [Category] Coronavirus, MERS, [키워드] Amino acid Analysis approved cause Cell cytoplasmic development domain ectodomain evaluated experiments expresse expression fused genetics growth humoral immunogenicity immunofluorescence Infection inoculated intraperitoneally MERS-CoV mice Middle East Neutralizing antibodies neutralizing antibody pathogenicity Rabies virus recombinant S1 and S2 Safe severe disease specific treatment spike glycoprotein subunits Symptom the S1 subunit transmembrane Vaccine Viral vector virus western blot [DOI] 10.1371/journal.pone.0223684 PMC 바로가기 [Article Type] Research Article